INTRODUCTION
During this video series, Dr.'s C. Michael Gibson and Manesh Patel provide what you need to know to enhance patient care and reduce stroke risk.
Launch Date/Release Date: August 20, 2025
Activity Expiration Date: July 31, 2026
TARGET AUDIENCE
This activity is designed for healthcare providers who are involved in the clinical care of preventing strokes among patients. This may include physicians, physician associates, registered nurses, nurse practitioners, and pharmacists.
LEARNING OBJECTIVES
Upon completion of this enduring material, participants should be able to:
Episode 1:
• Recognize the limitations of current anticoagulation therapies in stroke prevention.
• Describe the impact of undertreatment and residual stroke risk on patient outcomes.
Episode 2:
• Differentiate FXIa inhibition from traditional anticoagulants.
• Identify the potential clinical advantages of FXIa inhibitors.
Episode 3:
• Define residual stroke risk and explain why it remains in certain patient populations.
• Discuss strategies to reduce undertreatment in high-risk individuals.
Episode 4:
• Evaluate recent clinical trial data on FXIa inhibition.
• Interpret safety and efficacy results from key antithrombotic trials.
Episode 5:
• Apply emerging treatment approaches to individualized patient care.
• Assess how FXIa inhibitors may fit into future treatment pathways.
Episode 6:
• Use clinical decision-making frameworks to guide anticoagulant selection.
• Identify patient characteristics that may influence therapy choice.
Episode 7:
• Discuss emerging trends and therapies in stroke prevention.
• Anticipate future directions for anticoagulant development and implementation.
METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Review all modules associated with this course.
- Successfully complete the post-test (80% accuracy).
- Complete the CME/CE evaluation.
- The estimated time to complete this activity is 2.0 hours.
ACCREDITATION STATEMENTS
In support of improving patient care, this activity has been planned and implemented by RUSH University Medical Center and Practice Point Communications. RUSH University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statements
Rush University Medical Center designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Rush University Medical Center designates this enduring material for a maximum of 2.0 continuing nursing contact hour(s).
Rush University Medical Center designates this knowledge-based enduring material for a maximum of 2.0 contact hour(s) for pharmacists.
Disclosure Statements/FDA statement
Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.
It is the policy of Rush University Medical Center and the Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. All individuals in control of educational content must disclose all financial relationships with ineligible companies in the past 24 months. An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. All conflicts of interest, including potential ones, for individuals in control of educational content are mitigated prior to the planning, implementation, or evaluation of the continuing education activity.
The IPCE identifies the presence or absence of relevant financial relationships for all individuals in control of content including but not limited to planning committee members, course directors, invited presenters/authors, and staff through a standardized disclosure form. If a financial relationship is identified for the person in control of content, conflict mitigation strategies will be used to mitigate the financial relationship before they assume their role. .
DISCLOSURES
The speakers and planning committee members listed below have no relevant financial relationships with ineligible companies.
RUMC: Jennifer Comerford, MA, CHCP; Samantha Medina, BSN; Cecilia Merino; Alissa Shega, PharmD
PPC: Bronwyn Boyes; Colleen Goodchild; Julia Peterson; Jennifer Turnipseed
Individuals in control of content for this activity have the following relevant financial relationships to disclose and all financial relationships have been mitigated.
FACULTY DISCLOSURES
C. Michael Gibson, MD, MS, MA, FRCP, FAHA, FSCAI, FACCJean Elwing, MD
Research Grant: CSL Behring, Johnson & Johnson, Janssen Pharmaceuticals, NACAM Trial, SCAD Alliance
Consultant: Amgen, Angel/Avertix Medical, Anthos Therapeutics, Bayer Corporation, Bioclinica, Boehringer Ingelheim, Boston Clinical Research Institute, Boston Scientific, Bristol-Myers Squibb, Cardenal Therapeutics, Cardiovascular Research Foundation, CeleCor Therapeutics, CSL Behring, Daiichi Sanko, Duke Clinical Research Institute, Esperion, EXCITE International, Faraday Pharmaceuticals, Gilead Sciences, Inc., HeartFlow, Inari, Intellia Therapeutics, Janssen Pharmaceuticals, Johnson & Johnson Corporation, Lexaria, Lexicon, Lumanity, MashUp MD, MD Magazine, Medscape, Merck, MjHealth, NovoNordisk, Pfizer, PhaseBio, Revance Therapeutics, Samsung, SCAI, SFJ, Somahlution/Marizyme, Vectura, Web MD, Woman As One
Stock Options: Egnite, Flow Therapy, Fortress Biotech, Generable, HeartBeam, Lexaria, Nference, TribeMd
Royalties: UpToDate in Cardiovascular Medicine
Manesh Patel, MD
Research Grant: Bayer, Idorsia, NHLBI, PCORI, Regeneron
Consultant: Bayer, CohereMede STTR, Jansen, Medscape, NHLBI
Advisory Board: Bayer, CohereMed STTR, Jansen, Medscape, NHLBI
DISCLAIMER
The Rush University Medical Center and Practice Point Communications present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The Rush University Medical Center and Practice Point Communications assume no liability for the information herein.
PRIVACY POLICY
The Rush University Medical Center and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The Rush University Medical Center and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME, ANCC, or ACPE.
Rush University Medical Center and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
COPYRIGHT INFORMATION
Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:
The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
Supported by an independent educational grant from Bayer U.S.